Department of Medicinal Chemistry, Almirall S.A., R&D Centre, Laureà Miró 408-410, 08980 Sant Feliu de Llobregat, Catalonia, Spain.
Eur J Med Chem. 2011 Oct;46(10):4946-56. doi: 10.1016/j.ejmech.2011.07.054. Epub 2011 Aug 5.
A series of pyrido[3',2':4,5]furo[3,2-d]pyrimidines (PFP) were synthesized and tested for phosphodiesterase type 4 (PDE4) inhibitory activity, with the potential to treat asthma and chronic obstructive pulmonary disease (COPD). Structure-activity relationships within this series, leading to an increase of potency on the enzyme, is presented. Both gem-dimethylcyclohexyl moieties fused to the pyridine ring and the substitution at the 5 position of the PFP scaffold, proved to be key elements in order to get a high affinity in the enzyme.
一系列吡啶并[3',2':4,5]呋喃并[3,2-d]嘧啶(PFP)被合成并测试了其对磷酸二酯酶 4(PDE4)的抑制活性,具有治疗哮喘和慢性阻塞性肺疾病(COPD)的潜力。本文介绍了该系列化合物的构效关系,这导致了酶活性的增加。与吡啶环融合的双甲基环己基部分和 PFP 支架的 5 位取代基被证明是获得高酶亲和力的关键因素。